Christopher Wilfong is an Operating Partner at Two River, and has been a co-founder and held interim senior leadership roles in several Two River portfolio companies including Kite Pharma, Inc. (acquired by Gilead Sciences), Neogene Therapeutics, Inc. (acquired by AstraZeneca) and TRC 2004, Inc. (acquired by Candid Therapeutics). Prior to Two River, Mr. Wilfong was a Director at Trustbridge Partners, a China-based growth equity firm, where he led the US investment team and negotiated multiple US-China joint ventures and strategic partnerships in the healthcare and media industries. Prior to that, he was a Consultant at Bain & Company. Chris received his B.S. in Economics from the Wharton School of the University of Pennsylvania, and his MBA from the MIT Sloan School of Management.